TAIPEI and SAN DIEGO, Dec. 23, 2025 — Senhwa Biosciences, Inc. (TPEx: 6492) outlined progress across its AI-enabled drug development platform at its 2025 investor conference, positioning the company amid a generational shift in immuno-oncology.
With major immune-oncology products facing patent expirations before 2030, pharmaceutical companies are seeking next-generation assets that can be combined across tumor types. Senhwa said it is addressing that demand through a strategy that integrates artificial intelligence validation, precision clinical development, and global partnerships.
An independent analysis using Google DeepMind’s C2S-Scale biological AI model examined more than 4,000 drug candidates and highlighted Senhwa’s Silmitasertib (CX-4945) as a leading agent to enhance anti-tumor immunity. The study, supported by Google’s computing infrastructure and preclinical validation from Yale University, found that CX-4945 significantly improves tumor antigen presentation, a key mechanism for enabling immune recognition of cancer cells.
Senhwa said the DeepMind analysis and Yale data support CX-4945’s potential as an immune-sensitizing agent that could help convert immunologically “cold” tumors to “hot,” increasing their responsiveness to immunotherapy.
The company also announced a clinical collaboration with BeOne Medicines to evaluate its lead candidate Pidnarulex (CX-5461) in combination with BeOne’s PD-1 inhibitor tislelizumab. The collaboration will initially focus on pancreatic cancer and other advanced solid tumors, including immunotherapy-resistant melanoma.
CX-5461 is a first-in-class small molecule that stabilizes DNA G-quadruplex structures and inhibits RNA polymerase I. That dual mechanism induces replication stress in tumor cells and activates the innate immune cGAS–STING pathway, the company said, creating an immune-active tumor environment. Senhwa cited robust preclinical data supporting CX-5461’s use in combination with existing immunotherapies.
Senhwa framed CX-5461 as a pathway-level, multi-target asset designed to serve as a backbone for combination regimens across cancer types rather than a single-asset, indication-specific drug. The company said this positioning has drawn interest from multinational pharmaceutical partners.
Expected near-term catalysts include clinical data readouts for CX-5461 and CX-4945, expansion of global partnerships, potential licensing deals, and increased presence at major oncology conferences such as ASCO, AACR, and ESMO.
Senhwa said it has moved beyond early-stage discovery into building a scalable, AI-validated oncology platform focused on advancing differentiated science for patients, partners, and shareholders.
Leave a Reply